journal-of-clinical-endocrinology-and-metabolism

name

journal-of-clinical-endocrinology-and-metabolism

description

Use when targeting the Journal of Clinical Endocrinology and Metabolism or deciding whether a clinical-endocrinology or metabolism study fits this venue. Encodes the journal's broad endocrine-organ fit, the clinical-evidence and methodological bar, reporting-guideline and registration requirements, Endocrine Society/OUP house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice.

Journal of Clinical Endocrinology and Metabolism (journal-of-clinical-endocrinology-and-metabolism)

Journal positioning

The Journal of Clinical Endocrinology and Metabolism (JCEM, Endocrine Society / Oxford University Press) is the Endocrine Society's flagship clinical journal, publishing research across the full breadth of clinical endocrinology and metabolism — thyroid, adrenal, pituitary/neuroendocrine, bone and mineral, reproductive endocrinology, obesity, lipid, and diabetes/metabolism — with an emphasis on human, patient-oriented studies that inform endocrine diagnosis and management. Its defining expectation is a clinically important advance in the diagnosis, treatment, or pathophysiology of an endocrine or metabolic disorder in humans, not a narrow single-center series, a pure animal study with no human translation, or a diabetes-only paper better placed in a dedicated diabetes journal. Breadth across endocrine organs is a feature: JCEM is the generalist endocrine venue. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JCEM author instructions.

When to trigger

• The author names JCEM for a clinical-endocrinology or metabolism study across any endocrine organ system and wants a fit/framing check.
• An endocrine study must be re-framed around a patient-oriented diagnostic, therapeutic, or pathophysiologic question.
• The author is choosing between JCEM (broad endocrine), Diabetologia (diabetes-specific), and The Lancet Diabetes & Endocrinology (high-impact trials).
• The author needs the journal's reporting-guideline, registration, and human-endocrine-study expectations.

Scope & topic fit

• Thyroid, adrenal, and pituitary/neuroendocrine disorders: diagnosis, hormone assays, and management studies.
• Bone, mineral, and calcium metabolism: osteoporosis, parathyroid, and vitamin-D endocrinology.
• Reproductive and developmental endocrinology: PCOS, hypogonadism, fertility, and pubertal/growth disorders.
• Obesity, lipid, and energy metabolism with endocrine mechanism or clinical management endpoints.
• Diabetes and glucose metabolism as part of broad endocrine practice (with awareness of diabetes-dedicated venues).
• Endocrine clinical trials, cohorts, biomarker/hormone-assay validation, and pharmacologic/hormone-therapy studies in humans.

Method & evidence bar

• Studies must be adequately powered with prespecified, patient-centered endocrine endpoints; surrogate hormone endpoints need clinical justification.
• The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational work, PRISMA for systematic reviews, STARD for diagnostic/assay accuracy.
• Trials require prospective registration and the registration number; protocol/SAP are expected.
• Hormone assays and biomarker methods must be validated and described (platform, reference intervals, harmonization); analytic rigor is scrutinized.
• Observational claims must address confounding, bias, and missing data; causal language must match the design.
• Effect estimates need confidence intervals and absolute as well as relative measures; clinical significance must be argued.

Structure & house style

• Endocrine Society/OUP format with a structured abstract and a precis/context-and-significance statement; re-check current article types (Clinical Research Article, etc.) and limits on the live guide.
• The introduction frames the endocrine clinical question; the discussion states the diagnostic or management implication plainly.
• A CONSORT/STROBE/PRISMA/STARD flow diagram is expected for the relevant design.
• Tables/figures follow the journal's statistical-reporting standards; a supplement carries the protocol, full assay/statistical methods, and additional analyses.

Official-submission checklist

• Before giving submission-ready advice, read ../../resources/source-basis.md and ../../resources/official-source-map.md; start from the ICMJE/EQUATOR and Endocrine Society/OUP anchors, then cite the current JCEM page you checked.
• Search the live site for "JCEM Endocrine Society instructions for authors" and follow the current version.
• Re-check article types, abstract and precis format, and word/figure/reference limits.
• Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/STARD), assay-validation reporting, data/code-availability, and protocol/SAP submission.
• Re-check IRB/ethics and consent, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure.
• If the live official instructions conflict with this skill, the official instructions win.

Pre-submission self-check

• The study answers a patient-oriented endocrine diagnostic, therapeutic, or pathophysiologic question.
• Endocrine endpoints are prespecified and powered; trials are registered with the number in the manuscript.
• The correct reporting checklist (CONSORT/STROBE/PRISMA/STARD) is completed and attached.
• Hormone assays/biomarkers are validated and fully described.
• Confounding, bias, and missing data are addressed; causal language matches the design.
• IRB/consent, ICMJE disclosures, and a data-availability statement are prepared.

Common desk-reject triggers

• Single-center descriptive series with limited generalizability and no clear management change.
• Pure animal/cell endocrine studies with no human translation or clinical relevance.
• Unvalidated or poorly described hormone assays underpinning the main claim.
• Missing trial registration, protocol, or the required reporting checklist.
• Diabetes-only or single-trial work better placed in a dedicated diabetes or high-impact venue.

Re-routing decision

• Diabetes-focused clinical/epidemiologic or basic study → diabetologia.
• High-impact diabetes/endocrine trial with broad reach → the-lancet-diabetes-and-endocrinology.
• Diabetic kidney disease centered on nephrology → journal-of-the-american-society-of-nephrology / kidney-international.
• Endocrine surgery (thyroid/adrenal/pituitary surgical outcomes) → jama-surgery.
• Broad practice-changing endocrine trial → general medicine (jama / NEJM / The Lancet in the natural-science bundle).

Output format

[Fit] High / Medium / Low (one-line reason)
[Target] Journal of Clinical Endocrinology and Metabolism (Endocrine Society/OUP)
[Specialty tags] <thyroid / adrenal / pituitary / bone-mineral / reproductive / metabolism>
[Study design / reporting guideline] <RCT-CONSORT / cohort-STROBE / review-PRISMA / assay-STARD>
[Method/evidence] <power, assay validation, design, registration>
[Top risk] <the single most likely reason for rejection>
[Official items to re-check] <article type / registration / checklist / assay reporting / ethics / disclosures>
[Re-route suggestion] <if not a fit, a better-matched venue>